Validation pour Ingenuity377

vers la météo de la validation par utilisateur

Ingenuity377

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 49 - PMID ?

NODE , an inhibitor of SP NODE protein , is in Phase II clinical trial to treat chronic myeloid leukemia .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

     +---------------------SUBJ:V-N--------------------+                                                               
     |             +--------COMP:N-N(of)-------+       |                                 +--------OBJ:V-N--------+     
     |             |           +-MOD_ATT:N-ADJ-+       +-----------COMP:V-V(to)----------+      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       +COMP:V-N(in+                     |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |                     |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,II)
COMP:V-V(to) (be,treat)
OBJ:V-N (treat,leukemia)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 1

     +---------------------SUBJ:V-N--------------------+-----------------------COMP:V-N(to)----------------------+     
     |             +--------COMP:N-N(of)-------+       |                                 +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |                                 |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       +COMP:V-N(in+                     |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |                     |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,II)
COMP:V-N(to) (be,leukemia)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 2

                                                       +-----------------------COMP:V-N(in)----------------------+     
                                                       |           +-----------------MOD_ATT:N-N-----------------+     
     +---------------------SUBJ:V-N--------------------+           |            +-----------MOD_ATT:N-N----------+     
     |             +--------COMP:N-N(of)-------+       |           |            |        +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |           |            |        |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       |           |            |        |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |            |        |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,leukemia)
MOD_ATT:N-N (leukemia,II)
MOD_ATT:N-N (leukemia,trial)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 3

                                                       +-----------------------COMP:V-N(in)----------------------+     
                                                       |      +--------------------MOD_ATT:N-N-------------------+     
                                                       |      |    +-----------------MOD_ATT:N-N-----------------+     
     +---------------------SUBJ:V-N--------------------+      |    |            +-----------MOD_ATT:N-N----------+     
     |             +--------COMP:N-N(of)-------+       |      |    |            |        +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |      |    |            |        |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       |      |    |            |        |      |       +MOD_ATT:+     
     |             |           |       |       |       |      |    |            |        |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,leukemia)
MOD_ATT:N-N (leukemia,phase)
MOD_ATT:N-N (leukemia,II)
MOD_ATT:N-N (leukemia,trial)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 4

     +---------------------SUBJ:V-N--------------------+                                                               
     |             +--------COMP:N-N(of)-------+       |                                 +--------OBJ:V-N--------+     
     |             |           +-MOD_ATT:N-ADJ-+       +-----------COMP:V-V(to)----------+      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       +COMP:V-N(in+                     |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |                     |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,II)
COMP:V-V(to) (be,treat)
OBJ:V-N (treat,leukemia)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 5

     +---------------------SUBJ:V-N--------------------+-----------------------COMP:V-N(to)----------------------+     
     |             +--------COMP:N-N(of)-------+       |                                 +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |                                 |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       +COMP:V-N(in+                     |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |                     |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,II)
COMP:V-N(to) (be,leukemia)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 6

                                                       +-----------------------COMP:V-N(in)----------------------+     
                                                       |           +-----------------MOD_ATT:N-N-----------------+     
     +---------------------SUBJ:V-N--------------------+           |            +-----------MOD_ATT:N-N----------+     
     |             +--------COMP:N-N(of)-------+       |           |            |        +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |           |            |        |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       |           |            |        |      |       +MOD_ATT:+     
     |             |           |       |       |       |           |            |        |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,leukemia)
MOD_ATT:N-N (leukemia,II)
MOD_ATT:N-N (leukemia,trial)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)

Analyse 7

                                                       +-----------------------COMP:V-N(in)----------------------+     
                                                       |      +--------------------MOD_ATT:N-N-------------------+     
                                                       |      |    +-----------------MOD_ATT:N-N-----------------+     
     +---------------------SUBJ:V-N--------------------+      |    |            +-----------MOD_ATT:N-N----------+     
     |             +--------COMP:N-N(of)-------+       |      |    |            |        +------MOD_ATT:N-N------+     
     |             |           +-MOD_ATT:N-ADJ-+       |      |    |            |        |      +--MOD_ATT:N-ADJ-+     
     +----APPOS----+           |       +MOD_ATT+       |      |    |            |        |      |       +MOD_ATT:+     
     |             |           |       |       |       |      |    |            |        |      |       |        |     
 __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase II clinical trial to treat chronic myeloid leukemia .
APPOS (__NODE__,inhibiter)
COMP:N-N(of) (inhibiter,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
SUBJ:V-N (be,__NODE__)
COMP:V-N(in) (be,leukemia)
MOD_ATT:N-N (leukemia,phase)
MOD_ATT:N-N (leukemia,II)
MOD_ATT:N-N (leukemia,trial)
MOD_ATT:N-N (leukemia,treat)
MOD_ATT:N-ADJ (leukemia,chronic)
MOD_ATT:N-ADJ (leukemia,myeloid)